Showing results (191-200 of 230) with videos related to
Sort By:
Pageof 23
Nature Communications|September 23, 2021
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancerPanagiotis A Konstantinopoulos, Alexandre André B A da Costa, Doga Gulhan, et al.Proceedings of the National Academy of Sciences of the United States of America|September 29, 2012
Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapyShannon M McAuliffe, Stefanie L Morgan, Gregory A Wyant, et al.JAMA Oncology|July 28, 2022
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial CancerPanagiotis A Konstantinopoulos, Allison A Gockley, Niya Xiong, et al.JCO Precision Oncology|April 18, 2024
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker AnalysesPanagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2022
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III TrialJoyce F Liu, Mark F Brady, Ursula A Matulonis, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2022
Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian CancerMin Liu, Nabihah Tayob, Livius Penter, et al.Science (New York, N.Y.)|October 29, 2011
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapyTriona Ni Chonghaile, Kristopher A Sarosiek, Thanh-Trang Vo, et al.Gynecologic Oncology|October 20, 2023
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100Jonathan A Ledermann, Ronnie Shapira-Frommer, Alessandro D Santin, et al.Gynecologic Oncology|May 17, 2024
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparibJoyce F Liu, Niya Xiong, Robert M Wenham, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2019
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial CancerPanagiotis A Konstantinopoulos, Weixiu Luo, Joyce F Liu, et al.Pageof 23